Loading...
Hydantoin analogs inhibit the fully assembled ClpXP protease without affecting the individual peptidase and chaperone domains.
Fetzer, Christian Korotkov, Vadim S Sieber, Stephan A
Fetzer, Christian
Korotkov, Vadim S
Sieber, Stephan A
An error occurred retrieving the object's statistics
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2019-08-14
Submitted date
Files
Loading...
original manuscript
Adobe PDF, 995.11 KB
Loading...
supporting information
Adobe PDF, 5.1 MB
Other Titles
Abstract
Proteolysis mediated by ClpXP is a crucial cellular process linked to bacterial pathogenesis. The development of specific inhibitors has largely focused on ClpP. However, this focus was challenged by a recent finding showing that conformational control by ClpX leads to a rejection of ClpP binders. Thus, we here follow up on a hit molecule from a high throughput screen performed against the whole ClpXP complex and demonstrate that stable inhibition with high potency is possible. Further investigations revealed that the small molecule binds to ClpP without affecting its activity. Likewise, the molecule does not inhibit ClpX and retains the overall oligomeric state of ClpXP upon binding. Structure activity relationship studies confirmed structural constraints in all three parts of the molecule suggesting binding into a defined stereospecific pocket. Overall, the inhibition of ClpXP without affecting the individual components represents a novel mechanism with perspectives for further optimization for in situ applications.
Citation
Org Biomol Chem. 2019 Aug 14;17(30):7124-7127. doi: 10.1039/c9ob01339c. Epub 2019 Jul 17.
Publisher
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
1477-0539
EISSN
ISBN
ISMN
Gov't Doc #
Sponsors
License
Attribution-NonCommercial-ShareAlike 4.0 International